TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32097223

Group type: EXPERIMENTAL
Intervention: Delayed first newborn bath (at least 12 hours of age)
Number of subjects: 1463

Group type: COMPARATOR
Intervention: Routine first newborn bath (within 2 hours of age)
Number of subjects: 1463
Study: 34246197

Group type: EXPERIMENTAL
Intervention: αCT1
Number of subjects: 0
Study: 34203034

Group type: EXPERIMENTAL
Intervention: WhatsApp-delivered intervention (additional teaching material every two weeks for eight weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (received printed pamphlet only)
Number of subjects: 45
Study: 32970635

Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ganciclovir prophylaxis
Number of subjects: 0
Study: 32385158

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 35107050

Group type: EXPERIMENTAL
Intervention: AVT02 (40 mg dose)
Number of subjects: 392

Group type: COMPARATOR
Intervention: EU-reference product (adalimumab) (40 mg dose)
Number of subjects: 392

Group type: COMPARATOR
Intervention: US-reference product (adalimumab) (40 mg dose)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: All treatment arms (AVT02, EU-reference, US-reference)
Number of subjects: 392
Study: 33356889

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not exposed to surgical trauma)
Number of subjects: 0
Study: 33555912

Group type: EXPERIMENTAL
Intervention: CanDirect
Number of subjects: 245

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 245
Study: 32576225

Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1 antibody)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD 20 mg/m2 intravenously every 2nd week) + cyclophosphamide (50 mg per day, first 2 weeks in each 4 week cycle) + Atezolizumab
Number of subjects: 75

Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD 20 mg/m2 intravenously every 2nd week) + cyclophosphamide (50 mg per day, first 2 weeks in each 4 week cycle) + Placebo
Number of subjects: 75
Study: 33593675

Group type: EXPERIMENTAL
Intervention: 3D-printed custom open trays
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional custom open trays
Number of subjects: 22
Study: 34742230

Group type: EXPERIMENTAL
Intervention: LTN 200 mg
Number of subjects: 1471

Group type: EXPERIMENTAL
Intervention: LTN 100 mg
Number of subjects: 1471

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1471

Group type: EXPERIMENTAL
Intervention: LTN 200 mg, LTN 100 mg, LTN 50 mg
Number of subjects: 1471
Study: 35414799

Group type: EXPERIMENTAL
Intervention: Probiotics combined with standard triple therapy (Group B)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard triple therapy (Group A)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Gastrointestinal X-ray imaging based on intelligent algorithm
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: HP-positive patients
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: HP-negative patients
Number of subjects: 96
Study: 34318441

Group type: EXPERIMENTAL
Intervention: Norovirus GI strains
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HAdV
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both viruses (norovirus and HAdV)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Viral concentrations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Murine norovirus 1 (internal process control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Seasonal positivity rate
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HAdV and fecal coliform counts
Number of subjects: 100
Study: 35392832

Group type: EXPERIMENTAL
Intervention: Staged Integral Art-based Cognitive Intervention (SIACI) program, 16-week, 24-session
Number of subjects: 88

Group type: COMPARATOR
Intervention: Waitlist control group (receives SIACI after follow-up assessment)
Number of subjects: 88
Study: 32955693

Group type: EXPERIMENTAL
Intervention: Feedback intervention by letter
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Feedback intervention by telephone
Number of subjects: 1003

Group type: COMPARATOR
Intervention: No-contact control condition
Number of subjects: 1003
Study: 32001256

Group type: EXPERIMENTAL
Intervention: Non-Beall, DOAJ journals
Number of subjects: 410

Group type: COMPARATOR
Intervention: Beall journals
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Non-Beall journals
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: PubMed indexed journals
Number of subjects: 410

Group type: COMPARATOR
Intervention: Nonindexed journals
Number of subjects: 410
Study: 35548481

Group type: EXPERIMENTAL
Intervention: Music intervention applied to the observation group
Number of subjects: 96

Group type: COMPARATOR
Intervention: No music intervention applied to the control group
Number of subjects: 96
Study: 33736679

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 836
Study: 33115898

Group type: EXPERIMENTAL
Intervention: Tailored intervention group (TG) receiving healthy eating messages based on their stage of change.
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: General intervention group (GG) receiving the same healthy eating messages based on the Brazilian food guide.
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control group (CG) receiving messages on a different theme.
Number of subjects: 390
Study: 34275444

Group type: EXPERIMENTAL
Intervention: 20 cigarettes per pack (intervention)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Usual packs (control)
Number of subjects: 124
Study: 35666235

Group type: EXPERIMENTAL
Intervention: Video-based game exercise group (VGEG)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Structured closed kinetic chain exercise group (CKCEG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional exercise group (CEG)
Number of subjects: 45
Study: 35264220

Group type: EXPERIMENTAL
Intervention: Reading a book in bed
Number of subjects: 991

Group type: COMPARATOR
Intervention: Not reading a book in bed
Number of subjects: 991
Study: 32252103

Group type: EXPERIMENTAL
Intervention: Multi-joint (MJ) exercises
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Single-joint (SJ) exercises
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of multi-joint and single-joint (MJ+SJ) exercises
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups (MJ, SJ, MJ+SJ)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MJ and MJ+SJ groups
Number of subjects: 30
Study: 34986506

Group type: EXPERIMENTAL
Intervention: SQ sublingual immunotherapy tablets for grass pollen allergy
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: SQ sublingual immunotherapy tablets for tree pollen allergy
Number of subjects: 514
Study: 34619982

Group type: EXPERIMENTAL
Intervention: Endovascular intervention
Number of subjects: 64
Study: 34112032

Group type: EXPERIMENTAL
Intervention: Self-management support intervention
Number of subjects: 388

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 388
Study: 34507584

Group type: EXPERIMENTAL
Intervention: Parenting for Lifelong Health (PLH) intervention
Number of subjects: 552

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 552
Study: 34000386

Group type: EXPERIMENTAL
Intervention: Identical summary statistics in randomized controlled trials (RCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identical summary statistics in clinical cohorts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control datasets
Number of subjects: 0
Study: 34752971

Group type: EXPERIMENTAL
Intervention: Hand grip strength dependence on hand size
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hand grip strength dependence on wrist thickness
Number of subjects: 0
Study: 33652127

Group type: EXPERIMENTAL
Intervention: Rehabilitation Transition Plan (RTP) - includes Rehabilitation Discharge Plan (RDP) plus individualized, manualized care management via phone or videoconference for 6 months.
Number of subjects: 900

Group type: COMPARATOR
Intervention: Rehabilitation Discharge Plan (RDP) - includes patient/family education and referrals for continued care.
Number of subjects: 900
Study: 35249833

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined deep and superficial serratus anterior plane block (C‐SAPB)
Number of subjects: 0
Study: 33496413

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 mg / kg / h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Remifentanil (50‐100 μg / kg / h)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both Dexmedetomidine and Remifentanil
Number of subjects: 60
Study: 32805184

Group type: EXPERIMENTAL
Intervention: Statin+high‐dose EPA (1800 mg/day)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Statin+EPA (930 mg/day)+DHA (750 mg/day)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Statin only (control group)
Number of subjects: 130
Study: 36174630

Group type: EXPERIMENTAL
Intervention: Olaparib plus abiraterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus abiraterone
Number of subjects: 0
Study: 33034747

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT (ULD CT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Radiographs
Number of subjects: 69
Study: 36052819

Group type: EXPERIMENTAL
Intervention: Anodal tDCS to the left dlPFC
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 29
Study: 34755785

Group type: EXPERIMENTAL
Intervention: Ibuprofen/Caffeine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 32313031

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) followed by Resistance Training (RT) for 12 weeks each (n=9)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) following High-Intensity Interval Training (HIIT) for 12 weeks (n=9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Resistance Training (RT) following Habitual Course Observation (HC) for 12 weeks (n=8)
Number of subjects: 17
Study: 33549795

Group type: EXPERIMENTAL
Intervention: Resistance exercise (R) - 2 sets of 10 reps in eight resistance exercises
Number of subjects: 12

Group type: COMPARATOR
Intervention: Walking exercise (W) - 10 bouts of 2‐min walking at the speed corresponding to the onset of claudication pain with 2‐min interval among sets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Combined exercise (CO) - 1 set of 10 reps in eight resistance exercises + 5 bouts of 2‐min walking with 2‐min interval between
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control session (C) - resting in exercise room
Number of subjects: 12
Study: 35272897

Group type: EXPERIMENTAL
Intervention: Intraosseous morphine (10 mg) with standard IO antibiotic injection
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group received standard IO antibiotic injection
Number of subjects: 48
Study: 33238907

Group type: EXPERIMENTAL
Intervention: Collaborative infertility counseling (CIC) program, five sessions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 60
Study: 32198515

Group type: EXPERIMENTAL
Intervention: CYD-TDV
Number of subjects: 3927

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3927
Study: 33028305

Group type: EXPERIMENTAL
Intervention: Engagement with faith communities to address violence against women and girls (VAWG)
Number of subjects: 1949

Group type: EXPERIMENTAL
Intervention: Engagement with faith communities to address VAWG
Number of subjects: 1949
Study: 35312749

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study: 33655437

Group type: EXPERIMENTAL
Intervention: XP-endo Shaper (XPS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: ProTaper Next (PTN)
Number of subjects: 16
Study: 33452434

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 43
Study: 33244562

Group type: EXPERIMENTAL
Intervention: MCP® BCMC® strains (administered twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36447221

Group type: EXPERIMENTAL
Intervention: Renal replacement therapy (RRT)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Duration of RRT
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: SOFA score at initiation of RRT
Number of subjects: 287
Study: 33539946

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks
Number of subjects: 569

Group type: COMPARATOR
Intervention: Chemotherapy (topotecan or amrubicin)
Number of subjects: 569
Study: 33168839

Group type: EXPERIMENTAL
Intervention: Laxative immediately followed by Clostridium butyricum (CB) administration for 2 weeks (LP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laxative, interval of 2 weeks and CB administration for 2 weeks (L2P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CB administration for 2 weeks (P)
Number of subjects: 0
Study: 35168256

Group type: EXPERIMENTAL
Intervention: Invisalign aligners with SmartForce features and attachments
Number of subjects: 66

Group type: COMPARATOR
Intervention: Traditional fixed appliances (braces)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Posttreatment changes in aligner group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Posttreatment changes in braces group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Total OGS scores posttreatment
Number of subjects: 66
Study: 34310744

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 98

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 98
Study: 35378633

Group type: EXPERIMENTAL
Intervention: Lumentin® 44 (L44)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Diluted Omnipaque®
Number of subjects: 45

Group type: COMPARATOR
Intervention: MoviPrep®
Number of subjects: 45
Study: 33463027

Group type: EXPERIMENTAL
Intervention: 10‐kHz spinal cord stimulation (SCS) plus conventional medical management (CMM)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Conventional medical management (CMM) alone
Number of subjects: 211
Study: 33234645

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 33728530

Group type: EXPERIMENTAL
Intervention: Planned discharge education
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no planned discharge education)
Number of subjects: 100
Study: 33821332

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (8000 IU daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 39
Study: 34618364

Group type: EXPERIMENTAL
Intervention: Transobturator autologous rectus fascial sling (TO-AFS)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Transobturator tension-free vaginal tape (TVT-O)
Number of subjects: 132
Study: 33761932

Group type: EXPERIMENTAL
Intervention: Combination therapy of transcranial pulsed current stimulation (tPCS) at 400 Hz, 1 mA and transcutaneous electrical nerve stimulation (TENS) at 400 Hz, max 10 mA for 30 min, followed by 30 min of physiotherapy five times per week for 12 weeks.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Physiotherapy only for 30 mins per day five times per week for 12 weeks.
Number of subjects: 63
Study: 32580655

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6505

Group type: COMPARATOR
Intervention: Central End Point Committee (CEC) adjudication
Number of subjects: 6505

Group type: EXPERIMENTAL
Intervention: Investigators
Number of subjects: 6505
Study: 35403245

Group type: COMPARATOR
Intervention: Veliparib monotherapy (300-400 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Veliparib in combination with carboplatin/paclitaxel (120 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Veliparib exposure as a time-varying predictor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure-safety analysis
Number of subjects: 0
Study: 33237904

Group type: EXPERIMENTAL
Intervention: Systolic BP in Swedish cohorts
Number of subjects: 215274

Group type: EXPERIMENTAL
Intervention: Mendelian Randomization analysis in Swedish cohorts
Number of subjects: 215274

Group type: EXPERIMENTAL
Intervention: Systolic BP in UK-biobank
Number of subjects: 215274

Group type: EXPERIMENTAL
Intervention: Systolic BP for muscle-invasive bladder cancer (MIBC) in Swedish cohorts
Number of subjects: 215274

Group type: EXPERIMENTAL
Intervention: Diastolic BP for muscle-invasive bladder cancer (MIBC) in Swedish cohorts
Number of subjects: 215274

Group type: COMPARATOR
Intervention: Interaction between BP and NAT2
Number of subjects: 215274
Study: 32357807

Group type: EXPERIMENTAL
Intervention: Out of pocket expenses reported by participants with OCD
Number of subjects: 465
Study: 35490579

Group type: EXPERIMENTAL
Intervention: Patient-reported physical well-being
Number of subjects: 2894

Group type: EXPERIMENTAL
Intervention: Patient-reported functional well-being
Number of subjects: 2894

Group type: EXPERIMENTAL
Intervention: Patient-reported breast cancer subscale
Number of subjects: 2894

Group type: COMPARATOR
Intervention: ECOG PS
Number of subjects: 2894
Study: 32459724

Group type: EXPERIMENTAL
Intervention: AttraX Putty
Number of subjects: 100

Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 100
Study: 35809704

Group type: EXPERIMENTAL
Intervention: β‐caryophyllene (100 mg/daily with meal)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: β‐caryophyllene
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 34782532

Group type: EXPERIMENTAL
Intervention: Ferrous ascorbate (FeA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ferrous sulphate (FS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iron hydroxide polymaltose complex (IPC)
Number of subjects: 0
Study: 32535732

Group type: EXPERIMENTAL
Intervention: IL-6 inhibitors (tocilizumab, sarilumab, siltuximab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-6 inhibitors (tocilizumab, sarilumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-6 inhibitors
Number of subjects: 0
Study: 36220198

Group type: EXPERIMENTAL
Intervention: Incentivized lifestyle intervention program with stepwise addition of metformin
Number of subjects: 751

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 751
Study: 33471963

Group type: EXPERIMENTAL
Intervention: Telephone-delivered adherence therapy (8 weekly 30-min sessions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 40
Study: 36106493

Group type: COMPARATOR
Intervention: Intranasal isotonic saline (Group C)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 0.5 μg kg-1 (Group D0.5)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1.0 μg kg-1 (Group D1.0)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1.5 μg kg-1 (Group D1.5)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2.0 μg kg-1 (Group D2.0)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (ED95)
Number of subjects: 318
Study: 32145115

Group type: EXPERIMENTAL
Intervention: Modified health assessment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Management errors in calculated growth rates
Number of subjects: 40
Study: 33818305

Group type: EXPERIMENTAL
Intervention: nCBT
Number of subjects: 56

Group type: COMPARATOR
Intervention: WL
Number of subjects: 56
Study: 33077128

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC) supplementation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC) and Placebo (PLA)
Number of subjects: 10
Study: 34225282

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) applied for 30 mins once a day for 90 days
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group continued to receive anticholinergic drugs for 90 days
Number of subjects: 83
Study: 32350762

Group type: EXPERIMENTAL
Intervention: SSIDB with 2 ml of 1% lidocaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SSIDB with 1 ml of 1% lidocaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no digital block)
Number of subjects: 90
Study: 32948055

Group type: EXPERIMENTAL
Intervention: Single bout of ergometer cycling
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Targeted lipid spectrum analysis
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 15-hydroxyeicosatetranoic acid (HETE)
Number of subjects: 18
Study: 33111575

Group type: EXPERIMENTAL
Intervention: Attachment Video‐feedback (PCA‐AVI)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Psychoeducational intervention (PCA‐PI)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: PCA‐AVI
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both PCA groups
Number of subjects: 69
Study: 33903656

Group type: EXPERIMENTAL
Intervention: PAM intervention as an adjunct to usual care
Number of subjects: 101
Study: 33721863

Group type: EXPERIMENTAL
Intervention: Low Oral Health Literacy (OHL) score
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Unfavorable learning environment
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Nonwhite skin color
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Low socioeconomic status
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Low satisfaction with the last dental appointment
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Low OHL score (final model)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Nonwhite skin color (final model)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Low socioeconomic status (final model)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Low satisfaction with the last dental appointment (final model)
Number of subjects: 740
Study: 32665381

Group type: EXPERIMENTAL
Intervention: Oral switch antibiotic therapy after initial intravenous therapy
Number of subjects: 324

Group type: COMPARATOR
Intervention: Intravenous antibiotic therapy
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 324